ATyr Pharma Announces Research Study With Stanford Medicine Focusing On Understanding The Basic Mechanisms Of Immunosuppression In Glioblastoma Multiforme
ATyr Pharma Announces Research Study With Stanford Medicine Focusing On Understanding The Basic Mechanisms Of Immunosuppression In Glioblastoma Multiforme
aTyr Pharma, Inc. (NASDAQ:ATYR) ("aTyr" or "the Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that it has entered into a research agreement with Stanford Medicine. Michael Lim, M.D., Chair of the Department of Neurosurgery at Stanford Medicine, will serve as the principal investigator for the study. Dr. Lim's research focuses on understanding the basic mechanisms of immunosuppression in glioblastoma multiforme (GBM).
aTyr Pharma，Inc.(纳斯达克:ATYR)(" aTyr "或" 该公司")，一家临床阶段的生物技术公司，从其专有的tRNA合成酶平台中发现和开发首创药物。今天宣布，它已与Stanford Medicine签订了研究协议。Michael Lim万.D.，斯坦福医学院神经外科系主任，将担任该研究的首席研究员。Lim博士的研究重点是理解几种型胶质母细胞瘤(GBM)中的免疫抑制基本机制。